PsiThera Secures $47.5M Series A Led by Samsara Biocapital and Lightstone Ventures

Why It Matters

The sizable raise validates investor confidence in AI‑driven drug discovery and positions PsiThera to fast‑track novel therapies in a competitive biotech landscape.

Key Takeaways

• $47.5M Series A led by Samsara and Lightstone
• New CEO Eric Shaff appointed
• Focus on oral drugs for immune diseases
• Combines biophysics, AI, mechanistic biology
• Backed by Roivant, YK Bioventures, Eurofarma

Pulse Analysis

The biotech sector is witnessing a surge of capital toward companies that blend computational intelligence with traditional drug discovery. PsiThera’s $47.5 million Series A reflects a broader investor appetite for platforms that can model protein conformations and predict therapeutic outcomes, a niche that promises higher success rates and reduced development timelines. By securing backing from both venture firms and strategic biotech investors, PsiThera joins a growing cohort leveraging AI to de‑risk early‑stage pipelines.

PsiThera’s core technology integrates biophysical assays, high‑resolution modeling, and mechanistic biology to identify oral candidates for immune‑mediated and inflammatory conditions. This approach aims to overcome the delivery challenges that have limited biologics in these disease areas, potentially opening sizable market opportunities. The appointment of seasoned executive Eric Shaff signals a focus on operational scaling and partnership development, essential for translating computational hits into clinical candidates.

For the broader market, PsiThera’s funding round underscores the accelerating convergence of data science and pharmaceutical R&D. As larger players continue to acquire or collaborate with AI‑centric firms, startups that demonstrate tangible pipeline progress stand to attract further capital and strategic alliances. Investors will watch PsiThera’s upcoming preclinical milestones closely, as success could catalyze additional financing and reinforce the viability of AI‑first drug discovery models.

Deal Summary

Watertown‑based biotech PsiThera announced a $47.5 million Series A round to accelerate its protein‑state and computational‑intelligence drug platform. The round was led by Samsara Biocapital and Lightstone Ventures with participation from Roivant, YK Bioventures, Eurofarma Ventures and others.